Angion Biomedica Corp (ANGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANGN Stock Summary
- ANGION BIOMEDICA CORP's market capitalization of $21,079,592 is ahead of merely 6.89% of US-listed equities.
- ANGION BIOMEDICA CORP's stock had its IPO on February 5, 2021, making it an older stock than just 7.88% of US equities in our set.
- As for revenue growth, note that ANGN's revenue has grown 897.95% over the past 12 months; that beats the revenue growth of 98.79% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to ANGION BIOMEDICA CORP, a group of peers worth examining would be PTN, LCTX, BGRY, NBTX, and BNTC.
- Visit ANGN's SEC page to see the company's official filings. To visit the company's web site, go to www.angion.com.
ANGN Valuation Summary
- In comparison to the median Healthcare stock, ANGN's price/sales ratio is 86.27% lower, now standing at 0.7.
- ANGN's EV/EBIT ratio has moved up 14.6 over the prior 24 months.
Below are key valuation metrics over time for ANGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ANGN | 2023-01-20 | 0.7 | 0.4 | -1.1 | 1.8 |
| ANGN | 2023-01-19 | 0.7 | 0.4 | -1.1 | 1.7 |
| ANGN | 2023-01-18 | 0.7 | 0.4 | -1.2 | 1.7 |
| ANGN | 2023-01-17 | 0.8 | 0.4 | -1.2 | 1.7 |
| ANGN | 2023-01-13 | 1.1 | 0.6 | -1.8 | 1.1 |
| ANGN | 2023-01-12 | 1.0 | 0.6 | -1.6 | 1.3 |
ANGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ANGN has a Quality Grade of C, ranking ahead of 40.85% of graded US stocks.
- ANGN's asset turnover comes in at 0.097 -- ranking 265th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ANGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.097 | 0.587 | 2.99 |
ANGN Price Target
For more insight on analysts targets of ANGN, see our ANGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $59.33 | Average Broker Recommendation | 1.25 (Strong Buy) |
ANGN Stock Price Chart Interactive Chart >
ANGN Price/Volume Stats
| Current price | $0.70 | 52-week high | $2.94 |
| Prev. close | $0.70 | 52-week low | $0.59 |
| Day low | $0.64 | Volume | 179,200 |
| Day high | $0.71 | Avg. volume | 136,733 |
| 50-day MA | $0.83 | Dividend yield | N/A |
| 200-day MA | $1.11 | Market Cap | 21.08M |
Angion Biomedica Corp (ANGN) Company Bio
Angion Biomedica Corp. operates as a late-stage biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica serves customers in the State of New York.
Latest ANGN News From Around the Web
Below are the latest news stories about ANGION BIOMEDICA CORP that investors may wish to consider to help them evaluate ANGN as an investment opportunity.
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Angion Biomedica Corp. - ANGNNEW YORK, Jan. 18, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered… |
Angion (ANGN) Down on Merger Agreement With Private BiotechAngion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today! |
Neovasc, Aligos top healthcare gainers; Edesa, Angion lead losers'' packNeovasc NVCN +30%. Aligos Therapeutics (ALGS) +25%. Edesa Biotech EDSA -34%. Angion Biomedica ANGN -29%. |
Angion plummets 20% on merger agreement with Elicio TherapeuticsClinical-stage biotechnology company, Elicio Therapeutics to merge with a wholly-owned subsidiary of Angion Biomedica (ANGN) in an all-stock transaction |
ANGN Price Returns
| 1-mo | -12.51% |
| 3-mo | -30.00% |
| 6-mo | -34.58% |
| 1-year | -71.77% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -13.75% |
| 2022 | -72.01% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...